Study guide
2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations
Key Takeaways Explain This Topic AI
The liver possesses a dual blood supply receiving ~25% of cardiac output (1,500 mL/min): the portal vein provides 70-75% of blood flow (50-55% O2 supply), while the hepatic artery provides 25-30% of blood flow (45-50% O2 supply); the Hepatic Arterial Buffer Response (HABR) maintains total flow via adenosine-mediated arterial dilation when portal flow falls.
Hepatic clearance is categorized by extraction ratio (E_h): high extraction ratio drugs (E_h > 0.7, e.g., propofol, fentanyl, lidocaine) are perfusion-limited, whereas low extraction ratio drugs (E_h < 0.3, e.g., diazepam, lorazepam, warfarin, rocuronium) are enzyme-capacity-limited and sensitive to protein binding changes.
Phase I CYP450 functionalization reactions (CYP3A4, CYP2D6, CYP2E1) introduce polar groups and are impaired early by aging and cirrhosis; Phase II conjugation reactions (glucuronidation, sulfation) create water-soluble metabolites and remain relatively preserved until end-stage liver failure.
Cirrhosis leads to a hyperdynamic state with profound splanchnic vasodilation, low SVR, elevated cardiac output, and hepatorenal syndrome (HRS); Child-Pugh class C (10-15 points) and MELD >15-20 indicate severe surgical mortality risk.
Mendelson's syndrome risk is defined by gastric volume >25 mL (>0.4 mL/kg) and gastric pH <2.5; sodium citrate 30 mL immediately neutralizes acid without particulate injury, whereas IV metoclopramide enhances lower esophageal sphincter tone and accelerates gastric emptying.
Last updated: August 2026
2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations
The liver is the primary metabolic factory and clearance organ for anesthetic drugs. It plays a central role in protein synthesis (albumin, clotting factors, pseudocholinesterase), glucose homeostasis, bile formation, and waste detoxification. Advanced liver disease alters anesthetic pharmacokinetics via impaired drug metabolism, reduced plasma protein binding, altered volume of distribution, and complex multi-organ derangements including cirrhotic cardiomyopathy, portopulmonary hypertension, hepatopulmonary syndrome, and hepatorenal syndrome.
1. Hepatic Microcirculation & Dual Blood Supply
The liver receives 1,500 mL/min of blood , accounting for approximately 25% of resting cardiac output , but represents only 2.5% of total body weight. DUAL HEPATIC BLOOD SUPPLY
- PORTAL VEIN (~1,050-1,125 mL/min) HEPATIC ARTERY (~375-450 mL/min)
- 70% to 75% of Total Blood Flow • 25% to 30% of Total Blood Flow
- 50% to 55% of Oxygen Supply • 45% to 50% of Oxygen Supply
- Low Pressure (7 - 10 mmHg) • High Pressure (Systemic MAP ~90 mmHg)
- Venous drainage from stomach, spleen, • Direct celiac axis / common hepatic
- pancreas, and intestines artery branch
- │ │
- └───────────┬────────────┘
- ▼
- Hepatic Sinusoids
- Low-pressure capillary network
- Lined by fenestrated endothelial cells
- Space of Disse (lymph formation & protein exchange)
- Kupffer Cells (tissue macrophages)
- │
- ▼
- Central Veins
- │
- ▼
- Hepatic Veins
- │
- ▼
- Inferior Vena Cava (IVC)
- The Hepatic Arterial Buffer Response (HABR)
The Hepatic Arterial Buffer Response (HABR) is an intrinsic, semi-autonomous compensatory mechanism that maintains constant total hepatic blood flow. It operates in the microscopic space of Mall surrounding the hepatic triad:
Mechanism: Adenosine is constantly produced at a steady rate by periportal tissues and washed away into portal venous blood. If portal vein blood flow decreases (e.g., surgical retraction, laparoscopy, hypotension, splanchnic pooling), local adenosine washout decreases. Accumulated adenosine acts on vascular purinergic A2 receptors on hepatic arterioles, inducing potent hepatic arterial vasodilation and restoring total hepatic blood flow and oxygen delivery.
Unidirectional Limitation: The HABR is strictly unidirectional : a decrease in portal vein flow increases hepatic arterial flow, but changes in hepatic arterial flow do not alter portal venous flow!
Anesthetic Blunting: Volatile anesthetics (especially halothane > isoflurane > sevoflurane/desflurane) and severe cirrhotic endotoxemia blunt the HABR, rendering the liver vulnerable to ischemic injury during intraoperative hypotension.
2. Hepatic Drug Clearance & Extraction Ratio
Hepatic clearance ( C l H Cl_H C l H ) represents the volume of blood cleared of drug by the liver per unit of time: C l H = Q H × E H = Q H × ( C in − C out C in ) Cl_H = Q_H \times E_H = Q_H \times \left( \frac{C_{\text{in}} - C_{\text{out}}}{C_{\text{in}}} \right) C l H = Q H × E H = Q H × ( C in C in − C out )
Q H Q_H Q H = Total hepatic blood flow (~1,500 mL/min).
E H E_H E H = Hepatic Extraction Ratio (fraction of drug removed across a single pass through the liver; range 0.0 to 1.0).
C in C_{\text{in}} C in and C out C_{\text{out}} C out = Inflow and outflow drug concentrations.
High vs. Low Extraction Ratio Drugs
Extraction Category Extraction Ratio ( E H E_H E H ) Rate-Limiting Determinant of Clearance Effect of Δ \Delta Δ Hepatic Blood Flow ( Q H Q_H Q H ) Effect of Δ \Delta Δ Enzyme Activity ( C l int Cl_{\text{int}} C l int ) / Protein Binding ( f u f_u f u ) Anesthetic Examples
High Extraction Ratio (Perfusion-Limited) E H > 0.7 E_H > 0.7 E H > 0.7 Hepatic Blood Flow ( Q H Q_H Q H ) Proportional change: Clearance rises and falls directly with liver perfusion. Minimal effect. Changes in plasma protein binding or enzyme induction/inhibition do NOT significantly alter total clearance. Propofol , Ketamine , Etomidate , Fentanyl , Sufentanil , Morphine , Bupivacaine , Lidocaine , Meperidine, Propranolol
Low Extraction Ratio (Capacity-Limited / Enzyme-Dependent) E H < 0.3 E_H < 0.3 E H < 0.3 Intrinsic Hepatic Enzyme Capacity ( C l int Cl_{\text{int}} C l int ) & Free Fraction ( f u f_u f u ) Minimal effect. Alterations in hepatic blood flow have negligible influence on clearance rate. Major effect: Enzyme inhibition (e.g., CYP inhibitors) or decreased albumin (increased free fraction f u f_u f u ) dramatically alters clearance and clinical drug effect. Diazepam , Lorazepam , Midazolam (intermediate-low) , Warfarin , Phenytoin , Rocuronium , Vecuronium , Methohexital, Theophylline
3. Biotransformation: Phase I vs. Phase II Metabolism DRUG BIOTRANSFORMATION
- Lipophilic Parent Drug
- │
- ▼ Phase I Functionalization (CYP450 Superfamily, SER)
- Oxidation (Hydroxylation, Dealkylation, Deamination)
- Reduction
- Hydrolysis
- * Introduces or unmasks a polar functional group (-OH, -NH2, -SH, -COOH)
- * Vulnerable to aging, cirrhosis, and enzyme induction / inhibition
- │
- ▼ Intermediate Metabolite (Active, Inactive, or Toxic)
- │
- ▼ Phase II Conjugation (Cytosolic & Luminal Transferases)
- Glucuronidation (UDP-glucuronosyltransferase / UGT)
- Sulfation (Sulfotransferase)
- Glutathione conjugation (GST)
- Acetylation (NAT)
- * Couples a large hydrophilic endogenous substrate to form polar, water-soluble excretable product
- * Relatively preserved in aging and moderate cirrhosis
- │
- ▼
- Hydrophilic Excretable Metabolite (Excreted in Bile or Urine)
- Cytochrome P450 Isoenzymes & Anesthetic Interactions
CYP Isoenzyme Percentage of Drug Metabolism Major Anesthetic Substrates Inducers ( ↑ \uparrow ↑ Metabolism) Inhibitors ( ↓ \downarrow ↓ Metabolism / ↑ \uparrow ↑ Toxicity)
CYP3A4 / CYP3A5 ~50% of all pharmaceuticals Fentanyl, Sufentanil, Alfentanil, Midazolam, Lidocaine, Ropivacaine, Bupivacaine, Methadone, Dexamethasone Rifampin, Carbamazepine, Phenytoin, St. John's Wort, Barbiturates Azole antifungals (Ketoconazole), Erythromycin, Clarithromycin, Diltiazem, Grapefruit juice, Protease inhibitors
CYP2D6 ~20-25% Codeine (prodrug → \rightarrow → active morphine) , Tramadol , Oxycodone, Hydrocodone, Carvedilol, Ondansetron Dexamethasone (mild) Fluoxetine, Paroxetine, Quinidine, Bupropion. (Note: Genetic poor metabolizers get zero analgesia from codeine; ultra-rapid metabolizers risk fatal respiratory arrest)
CYP2E1 ~5% Volatile Anesthetics (Sevoflurane 2-5%, Isoflurane 0.2%, Desflurane 0.02%, Halothane 20%), Acetaminophen , Ethanol Chronic Ethanol consumption, Isoniazid Disulfiram, Acute Ethanol intoxication
- CYP2B6 ~5% Propofol , Ketamine , Methadone, Bupropion Phenobarbital, Rifampin Ticlopidine, Clopidogrel
- Acetaminophen Toxicity & N-Acetylcysteine (NAC) Rescue
Under normal conditions, 90% to 95% of acetaminophen undergoes Phase II glucuronidation and sulfation to non-toxic conjugates.
The remaining 5% to 10% is metabolized via CYP2E1 to the highly reactive, electrophilic, hepatotoxic intermediate NAPQI (N-acetyl-p-benzoquinone imine) .
NAPQI is rapidly detoxified by conjugation with endogenous Glutathione to form non-toxic mercapturic acid.
In acetaminophen overdose (>7.5-10 g in adults) or in chronic alcoholics with induced CYP2E1 and depleted glutathione stores: Glutathione is exhausted (>70% depletion) → \rightarrow → excess unbound NAPQI binds covalently to cysteinyl sulfhydryl groups of hepatocellular proteins → \rightarrow → mitochondrial permeability transition, ATP collapse, and centrilobular (Zone 3) hepatic necrosis .
Antidote: N-Acetylcysteine (NAC) restores hepatic glutathione stores and acts as a direct sulfhydryl surrogate to bind and neutralize NAPQI. Most effective when administered within 8 hours of ingestion.
- 4. Cirrhosis, Scoring Systems & Pathophysiologic Derangements
- Child-Turcotte-Pugh (CTP) vs. MELD Scoring CHILD-PUGH CLASSIFICATION (Mnemonic: "Pour Another Beer At Eleven")
- Parameters: PT/INR, Ascites, Bilirubin, Albumin, Encephalopathy
- Class A (5 - 6 Points): Well-compensated disease (Perioperative mortality <10%)
- Class B (7 - 9 Points): Significant functional impairment (Perioperative mortality ~30%)
- Class C (10 - 15 Points): Decompensated end-stage cirrhosis (Perioperative mortality 70-80%; elective surgery contraindicated)
Parameter 1 Point 2 Points 3 Points
Serum Total Bilirubin < 2.0 mg/dL < 2.0\text{ mg/dL} < 2.0 mg/dL ( < 34 μ mol/L < 34\ \mu\text{mol/L} < 34 μ mol/L ) 2.0 to 3.0 mg/dL 2.0\text{ to }3.0\text{ mg/dL} 2.0 to 3.0 mg/dL > 3.0 mg/dL > 3.0\text{ mg/dL} > 3.0 mg/dL ( > 50 μ mol/L > 50\ \mu\text{mol/L} > 50 μ mol/L )
Serum Albumin > 3.5 g/dL > 3.5\text{ g/dL} > 3.5 g/dL ( > 35 g/L > 35\text{ g/L} > 35 g/L ) 2.8 to 3.5 g/dL 2.8\text{ to }3.5\text{ g/dL} 2.8 to 3.5 g/dL < 2.8 g/dL < 2.8\text{ g/dL} < 2.8 g/dL ( < 28 g/L < 28\text{ g/L} < 28 g/L )
Prothrombin Time (INR) INR < 1.7 \text{INR} < 1.7 INR < 1.7 (PT prolongation < 4 s <4\text{ s} < 4 s ) INR 1.7 to 2.3 \text{INR } 1.7\text{ to }2.3 INR 1.7 to 2.3 (PT 4 − 6 s 4-6\text{ s} 4 − 6 s ) INR > 2.3 \text{INR} > 2.3 INR > 2.3 (PT prolongation > 6 s >6\text{ s} > 6 s )
- Ascites None Mild / Medically controlled Moderate to Severe / Refractory
- Hepatic Encephalopathy None Grade 1-2 (mild confusion, asterixis) Grade 3-4 (somnolence, stupor, coma)
MELD-Na Score: Utilizes objective continuous laboratory variables: Serum Bilirubin, Serum Creatinine, INR, and Serum Sodium . MELD score ranges from 6 to 40. A MELD score > 15 >15 > 15 is associated with significant perioperative morbidity and mortality; elective surgery is generally avoided when MELD > 20 >20 > 20 .
Multi-Organ Manifestations of Cirrhosis CIRRHOTIC MULTI-ORGAN CASCADE
- Portal Hypertension
- │
- ▼
- Massive Splanchnic Endothelial NO Release
- │
- ▼
- Profound Splanchnic Vasodilation
- │
- ┌──────────────────────────────┴──────────────────────────────┐
- ▼ ▼
- Marked Drop in SVR (Hyperdynamic State) Severe Effective Arterial Underfilling
- Elevated resting Cardiac Output (CO) • Baroreceptor unloading
- Low MAP & widened pulse pressure • Intense RAAS & Sympathetic activation
- Cirrhotic Cardiomyopathy (blunted inotropic • High non-osmotic ADH release
- response to stress, diastolic dysfunction, │
- prolonged QTc) ▼
- Avid Renal Na+ / H2O Retention
- Refractory Ascites & Hyponatremia
- Extreme Renal Vasoconstriction
- │
- ▼
- Hepatorenal Syndrome (HRS-AKI)
- Pulmonary & Renal Complications in Liver Disease
Hepatopulmonary Syndrome (HPS):
Triad: Advanced liver disease/portal hypertension, Intrapulmonary Vascular Dilatations (IPVDs) , and Arterial Hypoxemia (widened P A-a O 2 > 15 mmHg \text{P}_{\text{A-a}}\text{O}_2 > 15\text{ mmHg} P A-a O 2 > 15 mmHg ). Dilated precapillary and capillary vessels allow unoxygenated mixed venous blood to pass without full diffusion of oxygen (functional intrapulmonary shunt).
Hallmark Symptoms: Platypnea (dyspnea worsened in the upright position) and Orthodeoxia (arterial deoxygenation worsened in the upright position) due to gravitational pooling of blood to dilated bases.
Diagnostic Gold Standard: Contrast-Enhanced Transthoracic Echocardiography (Bubble Study): Agitated saline injected intravenously. Appearance of microbubbles in the left atrium after 3 to 6 cardiac cycles confirms transpulmonary shunting (appearance in 1-2 cycles indicates intracardiac right-to-left shunt like PFO).
Portopulmonary Hypertension (POPH):
Pulmonary arterial hypertension occurring in patients with portal hypertension: Mean Pulmonary Artery Pressure (mPAP) ≥ 20 − 25 mmHg \ge 20-25\text{ mmHg} ≥ 20 − 25 mmHg , Pulmonary Vascular Resistance (PVR) > 3 Wood units > 3\text{ Wood units} > 3 Wood units ( > 240 dyn ⋅ s / cm 5 > 240\text{ dyn}\cdot\text{s}/\text{cm}^5 > 240 dyn ⋅ s / cm 5 ), and Pulmonary Capillary Wedge Pressure (PCWP) ≤ 15 mmHg \le 15\text{ mmHg} ≤ 15 mmHg .
Critical Warning: Severe POPH (mPAP > 45 − 50 mmHg > 45-50\text{ mmHg} > 45 − 50 mmHg ) carries > 50 % >50\% > 50% perioperative mortality and is an absolute contraindication to liver transplantation and elective surgery unless optimized with targeted pulmonary vasodilators (e.g., Epoprostenol, Sildenafil).
Hepatorenal Syndrome (HRS-AKI):
Functional oliguric renal failure resulting from severe splanchnic vasodilation causing intense renal vasoconstriction and cortical ischemia in histologically normal kidneys.
Diagnostic Criteria: Cirrhosis with ascites, AKI by KDIGO criteria, no response after >=48 hours of diuretic withdrawal and volume expansion with IV Albumin (1 g/kg/day, max 100 g/day) , absence of shock, no recent nephrotoxic exposures, and absence of macroscopic structural renal disease (proteinuria < 500 mg/day <500\text{ mg/day} < 500 mg/day , absence of microhematuria, normal renal ultrasound).
Medical Management: Terlipressin (selective V1a vasopressin receptor agonist) or Norepinephrine infusion plus IV Albumin (20-40 g/day) to induce splanchnic vasoconstriction, increase effective circulating volume, and restore renal perfusion pressure. Definitive cure is orthotopic liver transplantation.
- 5. Gastrointestinal Motility, Aspiration Pathophysiology & Prophylaxis
- Mendelson's Syndrome & Aspiration Criteria
Pulmonary aspiration of gastric contents is a life-threatening anesthesia crisis. In 1946, Curtis Mendelson established the classical risk criteria for chemical pneumonitis:
Critical Gastric Volume: > 25 mL > 25\text{ mL} > 25 mL (or > 0.4 mL/kg > 0.4\text{ mL/kg} > 0.4 mL/kg ) .
Critical Gastric pH: < 2.5 < 2.5 < 2.5 . ASPIRATION PNEUMONITIS PATHOGENESIS
- Aspiration of Gastric Acid (pH <2.5) + Particulate Food Matter
- │
- ▼
- Direct Chemical Burn to Tracheobronchial Mucosa (<5 minutes)
- │
- ▼
- Destruction of Type I/II Alveolocytes & Capillary Endothelial Denudation
- │
- ▼
- Massive Influx of Neutrophils, Cytokines (TNF-alpha, IL-8), & Plasma Exudation
- │
- ▼
- Alveolar Edema, Loss of Surfactant, Atelectasis, Severe Bronchospasm
- │
- ▼
- Acute Respiratory Distress Syndrome (ARDS) & Intractable Hypoxemia
- High-Risk Patient Populations for Aspiration
Emergency surgical cases (non-fasting / full stomach).
Pregnancy (elevated progesterone decreases lower esophageal sphincter [LES] tone; gravid uterus displaces stomach cranially and horizontally; elevated gastrin increases acidity; considered full stomach ≥ 12 weeks \ge 12\text{ weeks} ≥ 12 weeks gestation through 48 hours postpartum).
Diabetes Mellitus with Autonomic Neuropathy (Gastroparesis) .
Bowel obstruction, ileus, acute peritonitis, active trauma / pain (sympathetic surge halts gastric emptying).
Hiatal hernia, severe GERD, morbid obesity ( ↑ \uparrow ↑ intra-abdominal pressure).
Opioid administration (profoundly delays gastric emptying).
GLP-1 Receptor Agonists (Semaglutide, Tirzepatide, Liraglutide): Profound delayed gastric emptying. ASA Consensus Guidance: For elective procedures, hold weekly GLP-1 agonists for 1 week prior to surgery, and daily formulations on the morning of surgery . If significant GI symptoms (nausea, vomiting, abdominal distension, severe reflux) persist on day of surgery, delay elective surgery or evaluate gastric volume via bedside Point-of-Care Ultrasound (POCUS) and proceed with Rapid Sequence Induction (RSI) .
Pharmacologic Aspiration Prophylaxis
Drug Class & Agent Dose & Administration Route Onset of Action Mechanism of Action Clinical Pearls & Contraindications
Non-Particulate Antacid (Sodium Citrate / Citric Acid - Bicitra) 30 mL PO 15-30 minutes prior to induction Immediate (1 - 5 min) Directly buffers and neutralizes pre-existing gastric hydrogen ions, raising gastric pH > 2.5 > 2.5 > 2.5 First-line in emergency obstetrics / RSI. Unlike particulate antacids (magnesium/aluminum hydroxide), non-particulate antacids do NOT cause foreign-body granulomatous lung injury if aspirated.
H2 Receptor Antagonist (Famotidine) 20 mg IV (or 20-40 mg PO) 30 to 60 minutes IV Competitively blocks histamine H2 receptors on gastric parietal cells, inhibiting basal and stimulated acid secretion Reduces gastric acid output and raises pH. Does not neutralize acid already present in the stomach.
Proton Pump Inhibitor (Pantoprazole) 40 mg IV 30 to 60 minutes IV Irreversibly inhibits H + / K + \text{H}^+/\text{K}^+ H + / K + -ATPase pump in gastric parietal cells Potent reduction in acid secretion and gastric volume. Administer > 30 − 60 min >30-60\text{ min} > 30 − 60 min prior to induction.
Gastrokinetic Prokinetic (Metoclopramide - Reglan) 10 mg IV slow push over 2-3 minutes 1 to 3 minutes IV Dopamine D2 receptor antagonist & 5-HT4 agonist; increases Lower Esophageal Sphincter (LES) tone , accelerates gastric emptying, relaxes pyloric sphincter Contraindications: Mechanical bowel obstruction, pheochromocytoma, Parkinson's disease. May induce Extrapyramidal Symptoms (EPS) / acute dystonia (treat with Diphenhydramine 25-50 mg IV).